menu
    • menu

    Company profile for Sichuan Kelun-Biotech Biopharmaceutical

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. focuses on research, development, and manufacturing of biopharmaceutical products. With expertise in innovative drug development, clinical trials, and large-scale manufacturing, Kelun-Biotech aims to provide advanced therapeutic solutions. Their platforms support new drug research, quality manufacturing, and global commercialization.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sichuan Kelun-Biotech BiopharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    No. 666 Xinhua Avenue Chengdu Cross-Strait Science and Technology Industry Dev...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://en.kelun-biotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kelun-Biotech Licenses Cancer Treatment to Crescent Biopharma
    Kelun-Biotech Licenses Cancer Treatment to Crescent Biopharma

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199605/0/en/Crescent-Biopharma-Announces-Transformational-Partnership-with-Kelun-Biotech-and-185-Million-Private-Placement-Accelerating-and-Expanding-Global-Pipeline-of-Next-Generation-Therape.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Annals Of Oncology Releases Phase II Study Results
    Annals Of Oncology Releases Phase II Study Results

    28 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-annals-of-oncology-publishes-results-of-phase-ii-study-of-sacituzumab-tirumotecan-monotherapy-for-urothelial-carcinoma-302627874.html

    PR NEWSWIRE
    28 Nov 2025
    Share Share
    Kelun-Biotech Initiates Phase III Trial For SAC-TMT with Keytruda
    Kelun-Biotech Initiates Phase III Trial For SAC-TMT with Keytruda

    24 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-announces-phase-iii-trial-of-sac-tmt-in-combination-with-keytruda-pembrolizumab-as-first-line-treatment-for-pd-l1-positive-nsclc-met-primary-endpoint-302624279.html

    PR NEWSWIRE
    24 Nov 2025
    Share Share
    Kelun-Biotech Unveils TROP2 ADC Sacituzumab Tirumotecan Data
    Kelun-Biotech Unveils TROP2 ADC Sacituzumab Tirumotecan Data

    09 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-presented-trop2-adc-sacituzumab-tirumotecan-results-from-multiple-clinical-studies-at-the-2025-cchio-congress-302609623.html

    PR NEWSWIRE
    09 Nov 2025
    Share Share
    Optitrop-Lung04 Study Results On Sacituzumab Tirumotecan
    Optitrop-Lung04 Study Results On Sacituzumab Tirumotecan

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-new-england-journal-of-medicine-publishes-results-of-phase-iii-optitrop-lung04-study-of-sacituzumab-tirumotecan-in-advanced-egfr-tki-resistant-nsclc-302588850.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    Kelun-Biotech Ph3 Data Favors Trastuzumab Botidotin Over T-DM1
    Kelun-Biotech Ph3 Data Favors Trastuzumab Botidotin Over T-DM1

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-presents-positive-phase-3-data-for-trastuzumab-botidotin-compared-to-t-dm1-at-2025-esmo-302588701.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search